Shortages of Ozempic and Wegovy that have been in place for more than two years have been resolved, as supplies of the popular diabetes and obesity treatments continue to improve, federal regulators said Friday.
The drugmaker Novo Nordisk can meet present and future demand in the U.S., the Food and Drug Administration said. But patients may still see some supply disruptions as the medications move from the manufacturer to distributors and then to pharmacies.
